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Characterization of a SILAC method for proteomic analysis of 
primary rat microglia
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1Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, 
USA
2Department of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, 
Tampa, FL, USA
Abstract
Microglia play important and dynamic roles in mediating a variety of physiological and 
pathological processes during the development, normal function and degeneration of the central 
nervous system. Application of SILAC-based proteomic analysis would greatly facilitate the 
identification of cellular pathways regulating the multifaceted phenotypes of microglia. We and 
others have successfully SILAC-labeled immortalized murine microglial cell lines in previous 
studies. In this study, we report the development and evaluation of a SILAC-labeled primary rat 
microglia model. Although the isotope labeling scheme for primary microglia is drastically 
different from that of immortalized cell lines, our de novo and uninterrupted primary culture 
labeling protocol (DUP-SILAC) resulted in sufficient incorporation of SILAC labels for mass 
spectrometry-based proteomic profiling. In addition, label incorporation did not alter their 
morphology and response to endotoxin stimulation. Proteomic analysis of the endotoxin-
stimulated SILAC-labeled primary microglia identified expected as well as potentially novel 
activation markers and pro-inflammatory pathways that could be quantified in a more 
physiologically relevant cellular model system compared to immortalized cell lines. The 
establishment of primary microglia SILAC model will further expand our capacity for global scale 
proteomic profiling of pathways under various physiological and pathological conditions. 
Proteomic data are available via ProteomeXchange with identifier PXD002759.
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Research on microglia, discovered nearly a century ago [1], had historically focused on their 
role as resident immune cells in the CNS in response to neuronal injury and invading 
pathogens and their contribution to the pathogenesis of various neurological disorders 
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including Parkinson’s and Alzheimer’s disease [2, 3]. Representing >10% of the cells in the 
CNS, microglia have increasingly been recognized as performing a highly dynamic role in 
early life CNS remodeling, formation of neuronal plasticity and maintenance of cellular 
homeostasis in an adult brain under physiologic and pathological conditions, in addition to 
their classical immune-related functions [4]. Underpinning their dynamic involvement in 
various cellular processes is a spectrum of “staged” and distinct microglial morphological 
and functional phenotypes [5]. The molecular mechanisms underlying the various microglial 
activation stages and the factors/pathways that regulate their shift from one stage to the next 
are not well understood.
MS-based proteomic analysis enables expression profiling of thousands of proteins in a 
single sample preparation, making it a powerful tool to identify cellular pathways associated 
with specific microglial activation stages. Highly desired, but currently not systematically 
evaluated for mass spectrometric pathway profiling, is a SILAC-based model with primary 
microglia which more closely resemble microglia in vivo than immortalized microglial cell 
lines. We have previously reported the establishment of an immortalized murine microglial 
cell line-based SILAC system where a near complete SILAC label incorporation (>98%) is 
conveniently achieved by propagating the immortalized cells in label-containing media 
through multiple and consecutive passaging [6, 7]. Primary microglia, however, may pose a 
particular challenge to achieving a sufficient isotopic label incorporation due to how primary 
microglia are prepared in culture [8–10]: a mixed glia culture (microglia and astroglia) are 
first established from newborn pup’s brain cells and microglia are then separated from 
astroglia two weeks later. No passaging is involved in the two-week time span during which 
various cell types including microglia undergo their in vitro maturation process.
To prepare SILAC-labeled primary microglia, we employed our de novo and uninterrupted 
primary culture SILAC labeling strategy (DUP-SILAC) of making light or heavy labeled 
amino acid pairs (arginine and lysine) available to microglial cells throughout their in vitro 
maturation process without the introduction of any disruptive steps that may interfere with 
the maturation of various cell types in the mixed culture system. Brains were harvested from 
newborn Sprague Dawley rat pups (Charles River), cortical and midbrain tissues were 
mechanically triturated and dispersed cells (8 × 106) were seeded to poly-D-lysine coated 
75-cm2 culture flasks [10] and maintained at 37°C in a humidified atmosphere of 5% CO2 
and 95% air in either the “Light” or “Heavy” SILAC media (10 mL/flask). Light SILAC 
media consisted of arginine and lysine-free DMEM supplemented with 10% dialyzed FBS, 2 
mM L-glutamine, 1% MEM non-essential amino acids, 1 mM sodium pyruvate, 50 units/mL 
penicillin, 50 μg/mL streptomycin, 10 mM HEPES, pH 7.4 and 100 μg/mL each of L-
arginine and L-lysine (Life Technologies). The Heavy SILAC media was made up of the 
same ingredients except that the light L-arginine and L-lysine were replaced with heavy 
labeled 13C6-15N4-L-arginine and 13C6-15N2-L-lysine (Cambridge Isotope) [7]. Four days 
later, fresh Light or Heavy SILAC media (5 mL/flask) were added to respective cultures. 
Two weeks after the start of the cultures, the flasks were placed on an orbital shaker and 
shaken at 120 rpm for 60 min. Media containing the detached microglia were collected and 
seeded in Light or Heavy SILAC media to poly-D-lysine coated 6-well culture plates (106 
cells/3 mL media/well) or Nunc 8-well glass chamber slides (2.5×104 cells/0.3 mL media/
chamber) and grown overnight before treatment.
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The primary rat microglia harvested from mixed glia cultures that had been grown for two 
weeks in the DMEM-based Light (D-Light) and Heavy (D-Heavy) SILAC media were first 
compared with those from mixed glia cultures grown in the traditional DMEM/F12-based 
media (D/F12) [10] prepared from same pool of rat brains. As shown in Fig. 1A, the D-Light 
and D-Heavy microglia morphologically resembled the D/F12 microglia, exhibiting the 
characteristic morphology of primary microglia in vitro [9,11]. The culture was highly pure 
(>98%) for microglia as revealed by immunostaining for Iba-1 (ionized calcium-binding 
adaptor molecule 1), a microglia-specific marker (Fig. 1B), consistent with our previous 
reports [12,13]. Only a tiny fraction of cells were immune-positive for astroglial marker glial 
fibrillary acidic protein (D/F12: 0.41%, n = 980; D-Light: 0.14%, n = 690; D-Heavy: 0.38%, 
n = 792). Functionally, D/F12, D-Light, and D-Heavy microglia were equally responsive to 
endotoxin lipopolysaccharide (LPS, 0.2–5 ng/mL)-induced production of nitric oxide (NO), 
a reporter for the M1 microglial activation marker, inducible NO synthase (iNOS, [14]) (Fig. 
1C).
We next determined label incorporation efficiency, a key determinant of whether these 
microglia would be suitable for SILAC-based proteomic profiling. Microglia (106) were 
harvested from D-Heavy mixed glia cultures at 9 days (the earliest in vitro microglia 
maturation time point under the condition), 2 and 3 weeks following initial seeding [8–10], 
washed 3× with PBS, and then resuspended in 40 μL of lysis buffer (100 mM Tris-HCl, 
pH7.6, 4% SDS, and 100 mM dithiothreitol) [7]. Microglia were lysed at 95°C for 5 min 
followed by a brief sonication and centrifuged for 5 min at 17 000 × g. For MS, 50 μg of 
protein were processed using the FASP method [15, 16], digested with trypsin-LysC, 
desalted using HYPER-SEP C18 columns as described [6], concentrated by vacuum 
centrifugation, and resuspended in 0.1% formic acid. For samples with a lower protein 
concentration, 12 μg of protein were processed using the GASP method [17]. Peptides were 
separated on an Acclaim PepMap C18 (75 μm × 50 cm) UPLC column (Thermo) using an 
EASY-nLC 1000 with gradient time ranging from 60 to 240 min (2–40% acetonitrile in 
0.1% formic acid). Mass spectrometric analysis was performed by a hybrid quadrupole-
Orbitrap instrument (Q Exactive Plus, Thermo), using a top 10 data-dependent acquisition 
method with a dynamic exclusion time of 20 s. Full scan and MS/MS resolution was 70 000 
and 17 500, respectively. Protein identifications were assigned through MaxQuant (version 
1.5.0.30) using the UniProt Rattus norvegicus database (November 2014, 38 912 entries). 
Carbamidomethyl (C) was set as a fixed modification and acetyl (protein N-terminus) and 
oxidation (M) were set as variable modifications. Additional specifications included 
designating trypsin/P as the enzyme used with the possibility of two missed cleavages, Lys8 
and Arg10 as the heavy SILAC labels, 20 ppm (first search)/4.5 ppm (recalibrated second 
search) mass tolerance for precursor ions and 20 ppm mass tolerance for fragment ions. The 
mass spectrometric raw data have been deposited to the ProteomeXchange Consortium [18] 
via the PRIDE partner repository with the dataset identifier PXD002759.
Using an abundant cellular protein beta actin (actin, cytoplasmic 1) as an example, the 
percentage of the label incorporation for the peptide VAPEEHPVLLTEAPLNPK was 
approximately 55 and 78% in microglia isolated from 9 day and 2-week old mixed glia 
cultures, respectively (Fig. 2A). The global-scale incorporation efficiency of heavy-labeled 
amino acids was determined by Heavy:Light ratios reported in MaxQuant for all identified 
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peptides where percent efficiency at the peptide level was calculated as 1-(1/ratio(H/L)) [19]. 
Average labeling efficiency was approximately 53.4 ± 6.1%, 67.6 ± 4.4% and 72.5 ± 3.1% 
(mean ± SEM) at the 9 day, 2 and 3 week timed intervals, respectively (Fig. 2B). The 
labeling efficiency of ~70% achieved in primary rat microglia cultures in this study are 
similar to that observed for primary murine neuronal cultures [20, 21], but lower than the 
95% efficiency observed for 20-day old primary astroglial cultures [22]. As reported for 
primary neuron SILAC labeling studies, two different sets of heavy SILAC labels 
(sometimes referred to as “Heavy” and “Medium”) may be used to exclude unlabeled 
proteins from the analysis [23,24]. This approach would bypass the need to account for 
labeling efficiency and could potentially reduce the risk of introducing variation, making it 
worthy of consideration in future experiments involving primary neural cells with limited 
proliferation capacity.
Next, we performed proteomic analysis of SILAC-labeled primary microglia after exposure 
to the M1 stage activator LPS, in order to test the quantitation accuracy using normalized 
ratios (which accounts for labeling efficiency) from MaxQuant through bioinformatic 
analysis of the SILAC datasets. D-Light and D-Heavy microglia in 6-well plates were 
treated in duplicate for 24 h with Light SILAC media (control) and Heavy SILAC media 
containing 1 ng/mL LPS, respectively. Afterwards, cells were rinsed with PBS, collected in 
lysis buffer and equal amounts of proteins from D-Light and D-Heavy microglia were 
combined and processed for mass spectrometric analysis.
Using a peptide and protein false discovery rate of 1.0% in MaxQuant, 2299 protein groups 
and 12 442 peptides were identified across replicates (n = 2 biological replicates with two 
experimental replicates). Numerous hallmarks of classical microglial activation were 
observed in response to LPS treatment, including up-regulation of STAT1, CD14, and 
TLR-2. As an example, raw data representing lower fold changes of the up- and down-
regulated proteins, SOD2 and LRP1, respectively, as well as induction of iNOS are shown in 
Fig. 3A–C. LPS-induced iNOS up-regulation in microglia was independently confirmed by 
indirect immunofluorescence analysis of the iNOS protein (Fig. 3D). Additionally, based on 
the resulting relative quantitation from SILAC-labeled primary microglia, bioinformatic 
analysis (IPA version 01-01) revealed LPS exposure to be a predicted upstream event (Fig. 
3E). The expression level of only a few targets was inconsistent with the Ingenuity 
Knowledge Base, which included the downregulation of LRP1 (low density lipoprotein 
receptor-related protein 1). LRP1 has been shown, however, to be involved in the anti-
inflammatory response of murine macrophages where LRP1 deficiency causes 
downregulation of alternative (anti-inflammatory) activation markers and enhances the M1 
response [25]. Given the importance of LRP1 in macrophage polarization, differential 
expression of LRP1 in microglia could be time-dependent where downregulation occurs at 
early time points (post-M1 stimulation) to prevent transition to an alternative activation 
phenotype. Future work is needed to investigate LRP1 regulation in the context of microglial 
phenotypic changes.
It should be noted that single amino acid (arginine) based-SILAC labeling of primary 
microglia has been reported previously [26, 27]. However a comprehensive characterization 
of the singly labeled cells in terms of possible phenotypic alterations post labeling, labeling 
Zhang et al. Page 4
Proteomics. Author manuscript; available in PMC 2016 May 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
efficiency time course, and quantitation accuracy using high-resolution mass spectrometry 
were not reported.
In summary, we report a comprehensive (morphological, biochemical and proteomic) 
characterization of a SILAC-based model for primary rat microglia. Even though it was not 
possible to consecutively passage the primary glial cultures, which is the approach used for 
SILAC labeling of immortalized microglial cell lines, the two-week de novo and 
uninterrupted primary culture SILAC (DUP-SILAC) labeling strategy achieved a label 
incorporation ratio of ~70%, a value comparable to that observed for murine primary neuron 
cultures [20, 21]. The SILAC-labeled primary rat microglia were suitable for MS-based 
proteomic analysis with nearly 2300 proteins identified. Furthermore, proteomic analysis 
revealed that the SILAC labeled primary rat microglia responded in a similar fashion as 
immortalized rat microglial cells to stimulation with LPS as defined by expression changes 
of known proteins and related pathways associated with LPS-induced classical activation. In 
light of their multifaceted phenotypic stages, the SILAC-based proteomic model with 
primary microglia, which are characteristically more closely related to microglia in vivo 
compared to immortalized cell lines and are more suitable for studies involving co-cultures 
of multiple neural cell types, should further facilitate the identification of distinct cellular 
pathways and unique regulators mediating the dynamic microglial responses to various 
activity-modulating agents under physiological and pathological conditions.
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Figure 1. 
Comparison of primary rat microglia prepared from mixed glia cultures grown for 2 weeks 
in regular and SILAC media. (A) Photomicrograph of microglia prepared in DMEM/F12 (D/
F12), DMEM light SILAC (D-Light) and DMEM heavy SILAC (D-Heavy) media. (B) 
Immunostaining. Microglia cultures were immunostained for microglial marker Iba-1 
(Abcam) and counter-stained with DAPI for cell nuclei (Invitrogen) [12]. (C) LPS-induced 
nitrite production. Microglia were stimulated with 0 (control), 0.2, 1 and 5 ng/mL LPS for 
24 h and amounts of nitrite released were measured and expressed as mean ± SEM as 
previously described [11]. *p<0.05 compared to control (n = 3, ANOVA with Bonferroni/
Dunn post hoc analysis). Scale bar: 20 μm in A and 16 μm in B.
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Figure 2. 
SILAC labeling efficiency. (A) Representative full scan mass spectra showing the peptide 
pair with the sequence VAPEEHPVLL-TEAPLNPK* from beta actin in microglia following 
9 days (top panel) and 2 weeks (bottom panel) of SILAC labeling. B. Overall labeling 
efficiency calculated based on heavy label incorporation in all identified peptides (n = 9780 
peptides).
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Figure 3. 
LPS-induced microglial differential expression and upstream regulator prediction. (A–C) 
Full scan, high resolution mass spectra of SILAC pairs. The peptide GDVITQVALQPALK* 
from superoxide dismutase (SOD2), is shown in A. The heavy:light ratio, generated by the 
MaxQuant, was 1.98, or 3.40 after normalization. The peptide MYDAQQQQVGTNK* from 
low density lipoprotein receptor-related 1 (LRP1) is shown in B. The heavy:light ratio was 
0.33, or 0.41 after normalization. The peptide YAGYQMPDGTIR* from iNOS is shown in 
C. A heavy:light ratio could not be calculated for this inducible protein since it was not 
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present in control cells. (D) Immunostaining analysis of LPS-induced iNOS upregulation in 
microglia. Cells were counter-stained with DAPI for cell nuclei. Scale bar: 16 m. (E) 
Upstream regulator analysis using Ingenuity Pathway Analysis predicts LPS to be an 
activated upstream regulator (central node) where known downstream targets are shown in 
the outer nodes. Outer nodes represent enzymes (diamond), kinases (triangle), transporters 
(trapezoid), and other proteins (circle) where red and green node color represents up- and 
down-regulation, respectively. Orange indicates predicted activation for LPS as an upstream 
regulator, while orange, yellow and grey arrows indicate predicted activating effect, 
inconsistent relationship, or reported effect with limited information on downstream target 
expression change. For biological replicates 1 and 2, the p-values were 3.52×10−22 and 
6.22×10−14, respectively, and the Z-scores were 5.267 and 4.358, respectively.
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